A deep-dive into the economics, IP strategy, and competitive dynamics shaping two divergent paths for branded generic pharmaceutical companies The […]
Two Roads to Generic Drug Profits: The US Niche Strategy vs. India’s Mass Market Model Read Post »
The pharmaceutical industry operates on a model where the expiration of a primary patent is no longer the end of
The Cliff Is Real, and the Numbers Are Getting Worse The pharmaceutical revenue cliff is not a metaphor. It is
The pharmaceutical industry spent roughly $2.3 billion and 12 years, on average, bringing a single new molecular entity to market
Every year, pharmaceutical companies abandon thousands of patents. They miss maintenance fee deadlines. They fail to validate patents in markets
Patent Gaps Pay: The Regional Launch Windows Hidden Inside Abandoned Drug Patents Read Post »
What FTO Actually Means (And What It Doesn’t) The Legal Definition and Its Limits Freedom-to-operate analysis is one of the
De-Risk Your Pipeline: The Definitive Guide to Freedom-to-Operate Analysis in Biopharma Read Post »
Humira, AbbVie’s blockbuster arthritis drug, generated more than $200 billion in cumulative revenue before biosimilar competitors could reach American patients
How Drug Companies Turn 20-Year Patents Into 40-Year Monopolies Read Post »
The Problem With Citation Counts A patent that has been cited 400 times sounds impressive. An IP manager can drop
The Problem Nobody Admits Out Loud Every large pharmaceutical company has the same conversation at some point. A blockbuster drug
After the Patent: Big Pharma’s Branded Generic Playbook Read Post »
Get fresh news and insights, drug patent expirations & more…
